ClinicalTrials.gg
WithdrawnNCT03012646Updated Apr 11, 2017

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

A Phase 2 interventional study of Inhaled Treprostinil in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by United Therapeutics. Withdrawn. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
33rd of 37
0 · median 32
Started
2017
with 3 others
Phase 2
7 of 38
none open now
Registered
24th of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 33rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 7 in phase 2, and was the 24th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Treprostinil
  • PH
  • COPD
  • 6 Minute Walk Test
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of WHO Group 3 PH associated with
  2. Subjects are required to have a right heart catheterization (RHC) within one year prior to the first dose of study drug with the following parameters:

    1. Pulmonary vascular resistance (PVR) ≥ 4 Wood Units (WU) and
    2. A left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) of ≤ 12 mmHg if PVR ≥ 4 WU to \< 6.25 WU or ≤ 15 mmHg if PVR ≥ 6.25 WU and
    3. A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg
  3. Clinical Diagnosis of COPD will be made using accepted Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria, including Baseline spirometry with the following documented parameters:

    1. \< 65% predicted, and
    2. FEV1/ FVC \< 70
  4. Baseline 6MWD ≥ 100 meters

Exclusion criteria

Exclusion criteria:

  1. The subject has a diagnosis of pulmonary arterial hypertension (PAH) or PH for reasons other than as outlined in inclusion criterion 3. This would include, but is not limited to, the concomitant presence of thromboembolic disease (acute or chronic), untreated or inadequately treated obstructive sleep apnea, connective tissue disease (including but not limited to systemic sclerosis/scleroderma, or systemic lupus erythematosus), sarcoidosis, interstitial lung disease,-1 infection, and other conditions under WHO Group 1, 2, 4, and 5 classifications.
  2. The subject has received any Food and Drug Administration (FDA)-approved medication for the treatment of PAH (ie, prostacyclin, prostacyclin receptor agonist, endothelin receptor antagonist [ERA], phosphodiesterase type 5 inhibitor [PDE5-I],or soluble guanylate cyclase [sGC] stimulator) within 60 days of the first dose of study drug, except for acute vasoreactivity testing.
  3. The subject has evidence of left-sided heart disease as defined by the following criteria per the most recent assessment:

    1. Left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) >15 mmHg (or >12 mmHg if pulmonary vascular resistance [PVR] ≥4 to \<6.25 WU)
    2. \<40% as assessed by either angiography or echocardiography.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Active Inhaled Treprostinil

    Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

    Drug: Inhaled Treprostinil

Interventions

  • Inhaled treprostinil (6 mcg/breath) administered four times daily

    Also known as: Tyvaso

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Among Participants through 48 Weeks

    The incidence of adverse events among participants throughout the 48-week study will be measured by the number of participants analyzed and the percentage of those participants who experienced an adverse event.

    Time frame: 48 weeks

Secondary outcomes

  1. Change in 6-minute Walk Distance (6MWD) from Baseline to Week 48

    Time frame: Baseline and Week 48

  2. Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to Week 48

    Time frame: Baseline and Week 48

  3. Change in Forced Expiratory Volume (FEV1) in One Second from Baseline to Week 48

    Time frame: Baseline and Week 48

  4. Change in Forced Vital Capacity (FVC) from Baseline to Week 48

    Time frame: Baseline and Week 48

  5. Change in Lung Diffusion Capacity (DLCO) from Baseline to Week 48

    Time frame: Baseline and Week 48

  6. Change in right ventricular ejection fraction (RVEF) as assessed via cMRI from Baseline to Week 48

    Time frame: Baseline and Week 48

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2017; primary completion for Apr 2019, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Jan 6, 2017
StartEst.
Apr 2017
Primary completionEst.
Apr 2019
CompletionEst.
Apr 2019
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03012646
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Apr 2017 (estimated)
Primary completion
Apr 2019 (estimated)
Completion
Apr 2019 (estimated)
Last update
Apr 11, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion